Compounds > 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene
Page last updated: 2024-12-06

1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene is a complex organic molecule with a specific structure and characteristics. Its importance in research arises from its potential applications in various fields:

**Structure and Characteristics:**

* It's a **diarylalkene** with two 4-hydroxyphenyl groups and one phenyl group attached to a but-1-ene backbone.
* The hydroxyl groups on the phenyl rings make it a **phenol derivative**.
* Its specific structure with conjugated double bonds and aromatic rings allows for potential applications in:

**Research Applications:**

* **Pharmaceutical Research:** It might exhibit biological activity as a:
* **Antioxidant**: The hydroxyl groups could act as free radical scavengers.
* **Anti-inflammatory**: Its structure could interact with inflammatory pathways.
* **Anti-cancer**: It might possess cytotoxic properties against certain cancer cells.
* **Materials Science:**
* **Polymer Synthesis:** It could be used as a monomer for synthesizing polymers with unique properties due to its rigid structure and hydroxyl groups.
* **Organic Electronics:** Its conjugated system might make it suitable for applications in organic electronics such as solar cells or organic light-emitting diodes (OLEDs).
* **Agricultural Research:**
* **Pesticide Development:** It could serve as a starting material for developing new pesticide compounds.
* **Plant Growth Regulator:** Its biological activity might affect plant growth and development.

**Important Considerations:**

* **Research is ongoing**: While the molecule has potential, its exact properties and applications are still under investigation.
* **Toxicity**: It's crucial to assess the potential toxicity of this molecule and its derivatives before any commercial application.

In summary, 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene is an interesting organic molecule with potential applications in diverse research areas. Its importance lies in its unique structure and the possibility of developing valuable compounds and materials from it. Further research is needed to fully understand its properties and applications.

1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID63059
CHEMBL ID149791
SCHEMBL ID639225
MeSH IDM0148716

Synonyms (27)

Synonym
tamoxifen bis-phenol
CHEMBL149791 ,
4,4''-(2-phenylbut-1-ene-1,1-diyl)diphenol
1,1-bis(4,4''-hydroxyphenyl)-2-phenylbut-1-ene
bdbm50121317
4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol
FT-0663304
phenol, 4,4'-(2-phenyl-1-butenylidene)bis-
1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene
1,1-bhpe
91221-46-4
1,1-bis(4-hydroxyphenyl)-2-phenyl-1-butene
SCHEMBL639225
DTXSID50238452
AKOS030254689
4-[1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl]phenol
AS-65436
4,4'-(2-phenylbut-1-ene-1,1-diyl)diphenol
1,1-bis(4'-hydroxyphenyl)-2-phenylbut-1-ene
BPKSDMHGDYTXLI-UHFFFAOYSA-N
4-(1-(4-hydroxylphenyl)-2-phenylbut-1-enyl)phenol
4,4-(2-phenylbut-1-ene-1,1-diyl)diphenol
mfcd00870103
B5114
T71450
CS-0316897
PD181966
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)IC50 (µMol)0.00610.00000.723732.7000AID1594506; AID1594508; AID68743
AromataseHomo sapiens (human)IC50 (µMol)24.88670.00001.290410.0000AID1322002; AID1710762; AID751070
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorHomo sapiens (human)EC50 (µMol)0.00050.00000.53054.4000AID1152694; AID1594509
Estrogen receptor betaHomo sapiens (human)EC50 (µMol)0.30690.00000.47954.8900AID1322006; AID1710766; AID751067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (57)

Processvia Protein(s)Taxonomy
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID751066Displacement of fluorescent ES2 from human recombinant ERalpha at 100 uM after 2 hrs by fluorimetric analysis relative to control2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
AID1594511Agonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ER-alpha-mediated transcriptional activity at 10 uM by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID237434Partition coefficient (logP)2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro.
AID1152695Agonist activity at ER in human MCF7:WS8 cells assessed as increase in cell growth by measuring DNA level at 10'-6 M after 7 days by fluorescence analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID751070Inhibition of human recombinant microsomal aromatase-mediated 7-methoxy-4-trifluoromethylcoumarin conversion to 7-hydroxytrifluoromethylcoumarin preincubated for 10 mins measured after 30 mins by fluorescence assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
AID751067Displacement of fluorescent ES2 from human recombinant ERbeta after 2 hrs by fluorimetric analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
AID473406Estrogenic activity at wild type ER alpha expressed in T47D:C:4:2 cells coexpressing estrogen response element by duel luciferase reporter gene assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1594510Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay relative to untreated control2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1710763Displacement of ES2 from recombinant human ER-alpha at 100 uM incubated for 2 hrs by fluorescence based assay relative to control2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
AID1594506Binding affinity to GST-tagged human ER alpha ligand-binding domain by TR-FRET assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID473418Displacement of [3H]estradiol from full-length human estrogen receptor beta assessed as relative binding affinity by radiometric assay relative to estradiol2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).
AID1152709Agonist activity at ER in human MCF7:WS8 cells assessed as increase in pS2 gene expression at 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID473417Displacement of [3H]estradiol from full-length human estrogen receptor alpha assessed as relative binding affinity by radiometric assay relative to estradiol2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).
AID1152703Agonist activity at ER in rat GH3 cells assessed as increase in prolactin mRNA level at 10'-13 to 10'-6 M after 48 hrs by RT-PCR analysis relative to estradiol2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID1594508Antagonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as reduction in E2-induced ER-alpha-mediated transcriptional activity by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID751057Inhibition of human recombinant microsomal aromatase using 7-methoxy-4-trifluoromethylcoumarin as substrate by Lineweaver-Burk plot analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.
AID239831Relative binding affinity for purified estrogen receptor 1 (ER-alpha)2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro.
AID1710764Displacement of ES2 from recombinant human ER-beta at 100 uM incubated for 2 hrs by fluorescence based assay relative to control2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
AID1152711Agonist activity at ER in human MCF7:WS8 cells assessed as increase in PgR gene expression at 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID1710762Inhibition of recombinant human aromatase incubated for 30 mins using fluorometric substrate 7-methoxy-4-trifluoromethylcoumarin in presence of NADPH cofactor mix by fluorometric assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
AID1152705Antagonist activity at ER in rat GH3 cells assessed as inhibition of estradiol-induced prolactin gene expression at 10'-10 to 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID239830Relative binding affinity for estrogen receptor 2 (ER-beta)2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro.
AID1322006Displacement of fluorescent ES2 from recombinant human ERbeta after 2 hrs in absence of light by fluorometric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
AID68743Antiestrogenic activity in MCF-7-2a cells as concentration required to reduce estradiol effect by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
AID239835Relative binding affinity for estrogen receptor 1 (ER-alpha) of lamb uterine cytosol2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro.
AID68739Estrogenic activity in MCF-7-2a cells as percent activation of 10e-8 M estradiol2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
AID1152694Agonist activity at ER in human MCF7:WS8 cells assessed as increase in cell growth by measuring DNA level after 7 days by fluorescence analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID41242In vivo antitumor activity against hormone-dependent MXT-M 3.2 mammary tumor in BDF1 mouse at a dose of 20 umol/kg.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
AID1322002Inhibition of recombinant human microsomal CYP19 using MFC as substrate measured after 30 mins by fluorometric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
AID71127Relative binding affinity for estrogen receptor of calf uterine cytosol with [3H]E22002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes.
AID473419Ratio of relative binding affinity for human ERbeta to relative binding affinity for human ERalpha2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).
AID1594509Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
AID1152716Effect on ER-alpha protein level in human MCF7:WS8 cells after 24 hrs by Western blot analysis relative to control2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID1322003Inhibition of recombinant human microsomal CYP19 at 50 uM using MFC as substrate measured after 30 mins by fluorometric analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
AID473401Activation of human ER in human MCF7:WS8 cells expressing estrogen responsive element by luciferase reporter gene assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1710766Displacement of ES2 from recombinant human ER-beta incubated for 2 hrs by fluorescence based assay2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
AID473407Estrogenic activity at wild type ER alpha D351G mutant expressed in T47D:C:4:2 cells coexpressing estrogen response element by duel luciferase reporter gene assay2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1322005Displacement of fluorescent ES2 from recombinant human ERalpha at 100 uM after 2 hrs in absence of light by fluorometric analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.
AID1152710Agonist activity at ER in human MCF7:WS8 cells assessed as increase in GREB1 gene expression at 10'-6 M after 48 hrs by RT-PCR analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
AID473402Estrogenic activity in human ERalpha expressing MCF7:WS8 cells assessed as stimulation of cell proliferation after 7 days2010Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
AID1152698Antagonist activity at ER in human MCF7:WS8 cells assessed as inhibition of estradiol-induced cell growth by measuring DNA level after 7 days treated at highesy drug concentration by fluorescence analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's1 (7.14)18.2507
2000's2 (14.29)29.6817
2010's8 (57.14)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cyclofenil
Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.		2.2110organic molecular entity
letrozole
[no description available]		2.1310nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		2.21101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
3,3'-Dimethylbisphenol A
[no description available]		2.2110bisphenol
bisphenol a
4,4'-isopropylidene diphenol: stimulates proliferative responses and cytokine productions of murine spleen cells and thymus cells in vitro. bisphenol : By usage, the methylenediphenols, HOC6H4CH2C6H4OH, commonly p,p-methylenediphenol, and their substitution products (generally derived from condensation of two equivalent amounts of a phenol with an aldehyde or ketone). The term also includes analogues in the the methylene (or substituted methylene) group has been replaced by a heteroatom.. bisphenol A : A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.		2.2110bisphenolendocrine disruptor;
environmental contaminant;
xenobiotic;
xenoestrogen
4,4'-bisphenol f
4,4'-bisphenol F: RN given refers to parent cpd. bisphenol F : A bisphenol that is methane in which two of the hydrogens have been replaced by 4-hydroxyphenyl groups.		2.2110bisphenol;
diarylmethane		environmental food contaminant;
xenoestrogen
f 6060
F 6060: structure		2.0510
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
[no description available]		2.7730stilbenoid
fulvestrant
Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.		2.512017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.2110olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
afimoxifene
afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.		2.5720phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		3.150stilbene
tamoxifen
[no description available]		2.0110stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
afimoxifene
[no description available]		2.0510
4-hydroxy-n-desmethyltamoxifen
4-hydroxy-N-desmethyltamoxifen: metabolite of tamoxifen in human bile		340stilbenoid
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		03.1750
Hormone-Dependent Neoplasms
[description not available]		02.420
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.1750
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9810
Experimental Mammary Neoplasms
[description not available]		02.3720